

INFUSION & MEDICAL CENTER

 Patient Na 	me DOB	Patient P	hone/Cell #
	Patient demographic and insurance information to be faxed with	Infusion O	rder Form
. Medical Info	ormation (Please select primary diagnosis and complete ICD10 Co	ode):	
Primary Diagnosis: Crohn's Disease (CD)		ICD-10 Code: K50	
ŕ	Ulcerative colitis (UC)	ICD-10 Code: K51	
	Other:	ICD-10 Co	ode:
. Clinical In	formation – Please fax with Infusion Order Form:		
• Clinica	I notes, labs, test supporting primary diagnosis		
Recent Lab Results including any recent antibody testing results		Patient	
	Screening Results, baseline: liver enzymes and bilirubin)	Weight: lbs.	
• Medica	ation List	_	
Previo	us Drug Therapy History, including therapies trialed and/or failed	Heigh	t: in.
	te of last infusion		
	nout period ofweeks desired prior to the initiation of this of Orders: Infusion center to obtain <u>liver enzymes and bilirubin</u> at week:		
	<u> </u>		
. Drug Ord	SKYRIZI® (risankizumab-rzaa) der:		J Code: J232
. Drug Ord	SKYRIZI® (risankizumab-rzaa) der: Dosing:		Ι
Induction Diagnosis	SKYRIZI® (risankizumab-rzaa) der: Dosing: Dosing Regimen	ad wook 8	Doses Authorized
Drug Ord Induction I Diagnosis	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 ar		Doses Authorized
Induction Diagnosis	SKYRIZI® (risankizumab-rzaa) der: Dosing: Dosing Regimen		Doses Authorized
Drug Ord Induction I Diagnosis For CD For UC	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 ar		Doses Authorized
Drug Ord Induction I Diagnosis For CD For UC	SKYRIZI® (risankizumab-rzaa) der: Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 ar 1200 mg administered via intravenous infusion at week 0, week 4 ar	and week 8	Doses Authorized 3 doses 3 doses
Drug Ord Induction I Diagnosis For CD For UC Pre-Medica	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 ar 1200 mg administered via intravenous infusion at week 0, week 4 ar No Pre-medications are recommended based on manufacture	and week 8 rer guideline	Doses Authorized 3 doses 3 doses
Drug Ord Induction I Diagnosis For CD For UC Pre-Medica	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 1200 mg administered via intravenous infusion at week 0, week 1200 mg administered via intrave	and week 8 rer guideline per approve	Doses Authorized 3 doses 3 doses
Drug Ord Induction I Diagnosis For CD For UC Pre-Medica	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered	rer guideline per approve	Doses Authorized 3 doses 3 doses es. ed ADR Protocol. Plus
Drug Ord Induction I Diagnosis For CD For UC Pre-Medica	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 1200 mg administered via intravenous infusion at week 0, week 1200 mg administered via intrave	rer guideline per approve	Doses Authorized 3 doses 3 doses es. ed ADR Protocol. Plus
Drug Ord Induction I Diagnosis For CD For UC Pre-Medica	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered	rer guideline per approve ng Intramed y insurance p	3 doses 3 doses 4 ADR Protocol. Plus providers.
Drug Ord Induction I Diagnosis For CD For UC Pre-Medica	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered	rer guideline per approve ng Intramed y insurance p	Doses Authorized 3 doses 3 doses es. ed ADR Protocol. Plus providers.
Drug Ord Induction I Diagnosis For CD For UC Pre-Medica Adverse Dr	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered	rer guideline per approve ng Intramed y insurance p	ed ADR Protocol. Plus providers. Date:
Drug Ord Induction Diagnosis For CD For UC Pre-Medica Adverse Dr Physician S Printed Physician S	SKYRIZI® (risankizumab-rzaa) Dosing: Dosing Regimen 600 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered via intravenous infusion at week 0, week 4 are 1200 mg administered	rer guideline per approve ng Intramed y insurance p	Doses Authorized 3 doses 3 doses es. ed ADR Protocol. Plus providers. Date: